$1 billion Keytruda deal illustrates value of royalty right sales for research institutes
Transformative agreement shows why niche investment model may appeal to cash-strapped life sciences innovators
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.